Respiratorius AB (publ)
Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company's products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was inc… Read more
Respiratorius AB (publ) (HF00) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.015x
Based on the latest financial reports, Respiratorius AB (publ) (HF00) has a cash flow conversion efficiency ratio of -0.015x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-481.00K) by net assets (€32.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Respiratorius AB (publ) - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Respiratorius AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Respiratorius AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Respiratorius AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PRINCIPAL FINANCIAL (PG4.SG)
STU:PG4
|
0.097x |
|
Top Systems-L
TA:TOPS
|
0.143x |
|
GRACO (GA8.SG)
STU:GA8
|
0.071x |
|
IMPLENIA N (I8T.SG)
STU:I8T
|
N/A |
|
SHAREHOLD VAL BET. - Dusseldorf Stock Exchang
DU:SVE
|
N/A |
|
Heartbeam Inc. Warrant
NASDAQ:BEATW
|
-0.689x |
|
NETFONDS AG VNA O.N.
F:NF4
|
N/A |
|
GAS2GRID Ltd
AU:GGX
|
0.014x |
Annual Cash Flow Conversion Efficiency for Respiratorius AB (publ) (2021–2024)
The table below shows the annual cash flow conversion efficiency of Respiratorius AB (publ) from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €30.10 Million | €-4.60 Million | -0.153x | +4.94% |
| 2023-12-31 | €26.50 Million | €-4.26 Million | -0.161x | -214.72% |
| 2021-12-31 | €56.81 Million | €-2.90 Million | -0.051x | -- |